Whalesbook
Indian Pharmaceutical Market Hits ₹2.4 Lakh Crore Milestone
The Indian pharmaceutical market (IPM) surged by 8.1% to reach ₹2,40,672 crore in the fiscal year 2025. Market intelligence firm Pharma Trac forecasts this strong growth trajectory to continue, projecting a similar 7.8-8.1% expansion rate for 2026.
Sun Pharma emerged as the top performer in terms of domestic sales revenue for 2025, generating ₹20,255 crore. Other significant contributors included Abbott India (₹14,277 crore), Cipla (₹13,484 crore), Mankind Pharma (₹13,321 crore), and Alkem Laboratories (₹9,900 crore). These figures highlight the sustained strength of India's pharmaceutical sector.
Growth Drivers and Segment Performance
Looking ahead to 2026, the market's expansion will be significantly fueled by key therapy areas. Cardiac treatments are expected to grow between 11-12%, followed by anti-diabetic (10-11%), neuro (9-10%), and respiratory segments (8-9%). These areas demonstrated strong performance in 2025 as well, with the cardiac segment leading at 13% growth.
The anti-diabetic segment saw a remarkable 9.4% growth in 2025, largely propelled by a 127.9% surge in GLP-1 agonist drugs such as Eli Lilly's Mounjaro and Novo Nordisk's Ozempic. Neuro and respiratory therapies also posted healthy gains of 9.4% and 10%, respectively.
Market Dynamics and Future Outlook
Sheetal Sapale of Pharma Trac noted that the projected slight moderation in cardiac segment growth for 2026 is due to the expanding base of this segment. For diabetes therapies, while GLP-1 agonists experienced over 100% growth recently, a period of consolidation is anticipated. This is attributed to the entry of branded generics, which may increase market volume but moderate value growth.
Pharma Trac categorizes the IPM into four key segments: high-growth lifestyle and therapies, demography-driven therapies for an aging population, mature acute therapies, and OTC/OTX categories. This segmentation provides a nuanced view of market drivers beyond traditional prescription channels. The analysis primarily uses organized drug trade data, acknowledging potential under-capture of certain channels like institutional sales and generic components.